Welcure Drugs

Has Welcure Drugs declared dividend?

No Dividend History Available

Who are the peers of the Welcure Drugs?

Welcure Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Welcure Drugs has below-average management and capital structure risks, with average growth, but boasts the highest 1-year return of 146.68% among its peers.

Peers: The peers of Welcure Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Mangalam Drugs, Source Natural, Bharat Immunolog, and Samrat Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Source Natural, while Good management risk is found at Divi's Lab., Torrent Pharma, and Samrat Pharma. Below Average management risk is seen at Parnax Lab, Welcure Drugs, and Bharat Immunolog, while Average management risk is noted at Mangalam Drugs. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, and Mangalam Drugs. Average growth is observed at Welcure Drugs, and the rest show Good growth. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Parnax Lab, while Good capital structure is found at Torrent Pharma and Source Natural. Below Average capital structure is noted at Welcure Drugs, Mangalam Drugs, and Bharat Immunolog.<BR><BR>Return Snapshot: Welcure Drugs has a 1-year return of 146.68%, which is the highest among its peers, while Bharat Immunolog has the lowest at -8.98%. The six-month returns for Mangalam Drugs, Parnax Lab, and Bharat Immunolog are negative.

What is the technical trend for Welcure Drugs?

As of May 8, 2025, Welcure Drugs shows a bullish technical trend supported by strong MACD, Bollinger Bands, and moving averages, though caution is advised due to a mildly bullish weekly Dow Theory trend.

As of 8 May 2025, the technical trend for Welcure Drugs has changed from mildly bullish to bullish. The weekly and monthly MACD are both bullish, indicating strong momentum. Bollinger Bands also reflect a bullish stance on both time frames. Daily moving averages are bullish, supporting the upward trend. The KST is bullish on both weekly and monthly charts, further confirming the positive outlook. However, the Dow Theory shows a mildly bullish trend on the weekly but no trend on the monthly, suggesting some caution. Overall, the current technical stance is bullish with strong indicators supporting this view.

Who are in the management team of Welcure Drugs?

As of March 2022, the management team of Welcure Drugs includes Sudhir Chandra (Managing Director), D C Jain, Gagan Juneja, and Mohd. Shahbaz Alam (Non-Executive & Independent Directors), along with Mitashi Bisaria (Director & Company Secretary), Sitaben S Patel, and Rajeev Mehra (Additional Directors). Each member plays a key role in the company's governance and management.

As of March 2022, the management team of Welcure Drugs consists of the following individuals:<BR><BR>1. D C Jain - Non-Executive & Non-Independent Director<BR>2. Sudhir Chandra - Managing Director<BR>3. Mitashi Bisaria - Director & Company Secretary<BR>4. Gagan Juneja - Non-Executive & Independent Director<BR>5. Mohd. Shahbaz Alam - Independent Director<BR>6. Sitaben S Patel - Additional Director<BR>7. Rajeev Mehra - Additional Director<BR><BR>Each member has distinct roles contributing to the governance and management of the company.

What does Welcure Drugs do?

Welcure Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1992, with recent quarterly net sales of ₹212 Cr and a net profit of ₹25 Cr as of March 2025. The company focuses on manufacturing bulk drugs and has a market cap of ₹138 Cr.

Overview:<BR>Welcure Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated on June 4, 1992, Welcure Drugs And Pharmaceuticals (WDPL) has undergone various developments, including a public issue in August 1994 to finance a project for manufacturing bulk drugs in Rajasthan. The latest reported quarterly results indicate net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 212 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 25 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 138 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 31.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.01 <BR>Return on Equity: 328.36% <BR>Price to Book: 97.99 <BR><BR>Contact Details:<BR>Address: B-9 & 10 Laxmi Towers, L S C Block-C Saraswati Vihar Delhi New Delhi : 110034 <BR>Tel: 91-011-2701 1428 <BR>Email: investor.welcure@gmail.com <BR>Website: https://welcuredrugs.com

Who are the top shareholders of the Welcure Drugs?

The top shareholders of Welcure Drugs are primarily individual investors, holding 98.99% of the shares, with Rahul Ratansingh Sikarwar being the largest individual shareholder at 9.78%. There are no institutional investors or pledged promoter holdings.

The top shareholders of Welcure Drugs primarily consist of individual investors, who hold a significant 98.99% of the company's shares. Among public shareholders, the highest individual shareholder is Rahul Ratansingh Sikarwar, with a holding of 9.78%. There are no institutional investors or mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

How big is Welcure Drugs?

As of 24th July, Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of 114.00 Cr, classifying it as a Micro Cap, with recent net sales of 46.64 Cr and net profit of 4.40 Cr over the latest four quarters. Data for shareholder's funds and total assets is unavailable.

As of 24th July, <BR><BR>Market Cap: Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of 114.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 46.64 Cr, while the sum of Net Profit for the same period is 4.40 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is the latest annual period. However, data for Shareholder's Funds and Total Assets is unavailable.

When is the next results date for Welcure Drugs?

Welcure Drugs will announce its results on 05 August 2025.

Welcure Drugs will declare its results on 05 August 2025.

Is Welcure Drugs overvalued or undervalued?

As of September 15, 2025, Welcure Drugs is considered an attractive investment due to its low PE ratio of 3.41 and significant undervaluation compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -28.11%.

As of 15 September 2025, the valuation grade for Welcure Drugs has moved from very attractive to attractive. The company is currently considered undervalued, given its low PE ratio of 3.41, a price-to-book value of 0.92, and an EV to EBITDA of 6.45. These ratios indicate that the stock is trading at a significant discount compared to its earnings and book value.<BR><BR>In comparison to its peers, Welcure Drugs stands out with a much lower PE ratio than Sun Pharma (33.52) and Divi's Lab (69.55), both of which are classified as expensive. Additionally, its PEG ratio of 0.01 further emphasizes its undervaluation relative to the industry. Despite recent stock performance trailing the Sensex, particularly with a year-to-date return of -28.11% compared to the Sensex's 4.67%, the fundamental metrics suggest that Welcure Drugs presents a compelling investment opportunity at its current price.

What is the bonus history of Welcure Drugs?

Welcure Drugs has announced a 1:10 bonus issue, with an ex-date and record date set for October 16, 2025. Shareholders will receive 1 additional share for every 10 shares held.

Welcure Drugs has a recent bonus issue history where they announced a 1:10 bonus issue. The ex-date for this bonus is set for October 16, 2025. This means that for every 10 shares held, shareholders will receive 1 additional share as a bonus. The record date for this bonus is also October 16, 2025. If you have any more questions about Welcure Drugs or need further details, feel free to ask!

How has been the historical performance of Welcure Drugs?

Welcure Drugs experienced a significant turnaround in the fiscal year ending March 2025, reporting net sales of 24.55 crore and a profit after tax of 2.17 crore, compared to losses in the previous year. This marked its first year of substantial revenue generation and profitability, with improved operating and profit margins.

Answer:<BR>The historical performance of Welcure Drugs shows significant changes, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Welcure Drugs reported net sales of 24.55 crore, a notable increase from previous years where sales were non-existent. The total operating income also rose to 24.55 crore, reflecting the same trend. The company's total expenditure, excluding depreciation, was recorded at 23.67 crore, which is a substantial increase from 0.23 crore in March 2024. Operating profit (PBDIT) for March 2025 was 2.79 crore, a recovery from a loss of 0.14 crore in the previous year. Profit before tax reached 2.78 crore, compared to a loss of 0.17 crore in March 2024, leading to a profit after tax of 2.17 crore, up from a loss of 0.17 crore. The earnings per share (EPS) improved to 0.02 from a negative 0.13 in the prior year, indicating a positive shift in profitability. The operating profit margin for March 2025 was 3.58%, and the profit after tax margin stood at 8.84%, both reflecting a strong performance compared to the previous years where these metrics were at zero. Overall, the financial results for March 2025 demonstrate a significant turnaround for Welcure Drugs, marking its first year of substantial revenue generation and profitability.

Are Welcure Drugs & Pharmaceuticals Ltd latest results good or bad?

Welcure Drugs & Pharmaceuticals Ltd's latest results are concerning, showing a 100% decline in net sales to ₹0.00 and an operating margin drop to 0.0%. The reported net profit of ₹1.07 crores was misleading, driven entirely by non-operating income, indicating serious operational distress and risks to future viability.

The latest results for Welcure Drugs & Pharmaceuticals Ltd are concerning and indicate significant operational distress. In Q3 FY26, the company reported net sales of ₹0.00, marking a dramatic 100% decline from the previous quarter. This is alarming as it suggests a complete cessation of commercial operations. <BR><BR>While the company reported a net profit of ₹1.07 crores, this figure is misleading as it was primarily driven by other income of ₹1.46 crores, which accounted for over 100% of the profit before tax. The core pharmaceutical business did not contribute to profitability, indicating serious issues with its operational viability.<BR><BR>The operating margin has also dropped to 0.0%, down from 17.31% in the previous quarter, highlighting a severe decline in operational performance. The return on equity (ROE) of 33.54% appears high but is not reflective of sustainable business operations, given the lack of revenue generation.<BR><BR>Overall, the results suggest a troubling situation for Welcure Drugs, with significant risks regarding its future viability and operational continuity. Investors should approach this stock with caution, as the combination of zero revenue and reliance on non-operating income raises serious red flags about the company's financial health.

Should I buy, sell or hold Welcure Drugs & Pharmaceuticals Ltd?

Why is Welcure Drugs & Pharmaceuticals Ltd falling/rising?

As of 03-Apr, the stock price of Welcure Drugs & Pharmaceuticals Ltd is rising to 0.25, reflecting a 4.17% increase due to strong investor participation and sector outperformance. However, it has significant long-term declines and is trading below all moving averages, indicating ongoing bearish trends.

As of 03-Apr, the stock price of Welcure Drugs & Pharmaceuticals Ltd is rising, currently at 0.25, which reflects a change of 0.01 or 4.17% increase. This rise can be attributed to a few key factors. Firstly, the stock has outperformed its sector by 5% today, indicating a relative strength compared to its peers. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 34.07% against the 5-day average, suggesting growing interest among investors.<BR><BR>However, it is important to note that despite the current rise, the stock has experienced significant declines over longer periods, with a year-to-date drop of 40.48% and a one-year decline of 68.22%. Furthermore, the stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), which typically indicates a bearish trend. The stock also hit a new 52-week low of Rs. 0.23 earlier today, which could have contributed to volatility in its price.<BR><BR>In summary, while the stock is currently rising due to increased investor participation and sector outperformance, it is essential to consider the broader context of its recent performance and the challenges it faces.

Why is Welcure Drugs & Pharmaceuticals Ltd falling/rising?

As of 04-Apr, Welcure Drugs & Pharmaceuticals Ltd's stock price has risen to Rs. 0.25, up 4.17%, driven by increased investor interest and sector outperformance. However, the stock has significant long-term declines and underlying weaknesses, including high debt and operating losses.

As of 04-Apr, Welcure Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs. 0.25, which reflects an increase of Rs. 0.01 or 4.17%. This rise can be attributed to several factors. Firstly, the stock has outperformed its sector by 5% today, indicating a relative strength compared to its peers. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 34.07% against the 5-day average, suggesting growing interest in the stock.<BR><BR>Despite the positive movement today, it is important to note that the stock has faced significant declines over longer periods, with a year-to-date drop of 40.48% and a staggering 68.22% decline over the past year. The stock is also trading below its moving averages across various time frames, which typically indicates bearish sentiment. However, the company has reported strong financial results, with net sales growing by 1,337.40% and profit after tax increasing by 2,034.42% over the last nine months, which may contribute to the current positive sentiment.<BR><BR>In summary, while the stock is rising today due to improved investor participation and sector outperformance, it remains under pressure from its historical performance and long-term fundamentals, which show weaknesses such as operating losses and a high debt-to-EBITDA ratio.

Why is Welcure Drugs & Pharmaceuticals Ltd falling/rising?

As of 05-Apr, the stock price of Welcure Drugs & Pharmaceuticals Ltd is currently at 0.25, reflecting a 4.17% increase today despite significant declines over the past week, month, and year. The rise is attributed to increased investor interest and outperformance against its sector, although the stock remains below its moving averages and has recently hit a new 52-week low.

As of 05-Apr, the stock price of Welcure Drugs & Pharmaceuticals Ltd is rising, currently at 0.25, which reflects a change of 0.01 or an increase of 4.17%. This rise comes despite the stock's overall negative performance in the past week, month, and year, where it has seen declines of 3.85%, 16.67%, and 68.22%, respectively. <BR><BR>Today's performance indicates that the stock has outperformed its sector by 5%, which may contribute to the positive movement in its price. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 34.07% against the 5-day average, suggesting growing interest among investors. <BR><BR>However, it is important to note that the stock is trading below its moving averages across various time frames, indicating a longer-term downward trend. Furthermore, the stock hit a new 52-week low of Rs.0.23 earlier today, which could have influenced the volatility in its price. Overall, while the stock is experiencing a rise today, it is amidst a backdrop of significant declines in its historical performance.

Which are the latest news on Welcure Drugs?